Literature DB >> 12853754

MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients.

Milena Nasi1, Vanni Borghi, Marcello Pinti, Cristian Bellodi, Enrico Lugli, Stefania Maffei, Leonarda Troiano, Luca Richeldi, Cristina Mussini, Roberto Esposito, Andrea Cossarizza.   

Abstract

P-glycoprotein, a membrane-localized protein transporter, codified by the MDR1 gene, influences the response to pharmacological treatments, including antiretroviral drugs. MDR1 polymorphism C3435T is correlated with the functionality of the protein. We investigated the influence of this polymorphism in the reconstitution of the peripheral CD4 T cell pool in 149 drug-naive HIV-positive patients starting highly active antiretroviral therapy. The MDR1 C3435Tpolymorphism did not influence response to therapy, suggesting no disadvantages for individuals with a different genotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853754     DOI: 10.1097/00002030-200307250-00016

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  16 in total

1.  Future Perspectives for Brain Pharmacotherapies: Implications of Drug Transport Processes at the Blood-brain Barrier.

Authors:  Dirk M Hermann
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

2.  Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+ T cell count after antiretroviral therapy in drug-naïve HIV-positive patients.

Authors:  Milena Nasi; Marcello Pinti; Roberto Bugarini; Leonarda Troiano; Enrico Lugli; Cristian Bellodi; Cristina Mussini; Vanni Borghi; Tommaso Trenti; Fiorella Balli; Roberto Esposito; Andrea Cossarizza
Journal:  Immunogenetics       Date:  2005-10-18       Impact factor: 2.846

3.  Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.

Authors:  Xia Liu; Qing Ma; Yan Zhao; Weiwei Mu; Xin Sun; Yuewu Cheng; Huiping Zhang; Ye Ma; Fujie Zhang
Journal:  Pharmacotherapy       Date:  2017-09-03       Impact factor: 4.705

Review 4.  The dawn of precision medicine in HIV: state of the art of pharmacotherapy.

Authors:  Ying Mu; Sunitha Kodidela; Yujie Wang; Santosh Kumar; Theodore J Cory
Journal:  Expert Opin Pharmacother       Date:  2018-09-20       Impact factor: 3.889

Review 5.  Host-Directed Antiviral Therapy.

Authors:  Naveen Kumar; Shalini Sharma; Ram Kumar; Bhupendra N Tripathi; Sanjay Barua; Hinh Ly; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

6.  CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.

Authors:  Natella Y Rakhmanina; Michael N Neely; Ron H N Van Schaik; Heather A Gordish-Dressman; Keetra D Williams; Steven J Soldin; John N van den Anker
Journal:  Ther Drug Monit       Date:  2011-08       Impact factor: 3.681

Review 7.  Human genetic variability and HIV treatment response.

Authors:  David W Haas
Journal:  Curr HIV/AIDS Rep       Date:  2006-07       Impact factor: 5.071

Review 8.  Pharmacokinetics of antiretroviral therapy in HIV-1-infected children.

Authors:  Pieter L A Fraaij; Jeroen J A van Kampen; David M Burger; Ronald de Groot
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

9.  The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.

Authors:  Samir K Gupta; Susan L Rosenkranz; Yoninah S Cramer; Susan L Koletar; Lynda A Szczech; Valerianna Amorosa; Stephen D Hall
Journal:  AIDS       Date:  2008-10-01       Impact factor: 4.177

10.  Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4.

Authors:  Andrew Owen; Becky Chandler; Patrick G Bray; Stephen A Ward; C Anthony Hart; David J Back; Saye H Khoo
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.